Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

被引：4

作者：

Sims, Robert B. ^{[1
]}

机构：

[1] Dendreon Corp, Seattle, WA 98121 USA

来源：

JOURNAL OF CANCER | 2011年 / 2卷

关键词：

sipuleucel-T; metastatic castrate resistant prostate cancer (mCRPC);

D O I：

10.7150/jca.2.357

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population.

引用

页码：357 / 359

页数：3

共 7 条

[1]

Burch PA, 2000, CLIN CANCER RES, V6, P2175

[2] Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer [J].

Higano, Celestia S. ;

Schellhammer, Paul F. ;

Small, Eric J. ;

Burch, Patrick A. ;

Nemunaitis, John ;

Yuh, Lianng ;

Provost, Nicole ;

Frohlich, Mark W. .

CANCER, 2009, 115 (16) :3670-3679

[3] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[4] CD54 is a surrogate marker of antigen presenting cell activation [J].

Sheikh, N. A. ;

Jones, L. A. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (09) :1381-1390

[5]

Sheikh NA, 2010, WASH DC ANN M AM ASS

[6] Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells [J].

Small, EJ ;

Fratesi, P ;

Reese, DM ;

Strang, G ;

Laus, R ;

Peshwa, MV ;

Valone, FH .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3894-3903

[7] Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer [J].

Small, Eric J. ;

Schellhammer, Paul F. ;

Higano, Celestia S. ;

Redfern, Charles H. ;

Nemunaitis, John J. ;

Valone, Frank H. ;

Verjee, Suleman S. ;

Jones, Lori A. ;

Hershberg, Robert M. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3089-3094

← 1 →